Evidence map›Paper›PMID 17635609›Full record

ArticleImmunology2007

Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences.

Kayvan R Niazi, Maria-Teresa Ochoa, Peter A Sieling, Nanette E Rooke, Anna K Peter, Pamela Mollahan, Micah Dickey, Shahrooz Rabizadeh, Thomas H Rea, Robert L Modlin

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.Molecular therapy. Methods & clinical development · 2017
    Article
  5. Article
  6. The future of human DNA vaccines.Journal of biotechnology · 2012
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kayvan R NiaziDiscovery Translation Unit, Buck Institute, Novato, CA, USA.
Maria-Teresa Ochoa
Peter A Sieling
Nanette E Rooke
Anna K Peter
Pamela Mollahan
Micah Dickey
Shahrooz Rabizadeh
Thomas H Rea
Robert L Modlin
Buck Institute for Research on Aging · USUniversity of California, Los Angeles · USUniversity of Southern California · US

Funding

CD1-targeted Vaccination against TuberculosisU01AI056489 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2003 to 2007
$2.0M
NIAID NIH HHS AI056489NIAID NIH HHS U01 AI056489
6 · The paper itself

Abstract

Distinct CD4(+) T-cell epitopes within the same protein can be optimally processed and loaded into major histocompatibility complex (MHC) class II molecules in disparate endosomal compartments. The CD1 protein isoforms traffic to these same endosomal compartments as directed by unique cytoplasmic tail sequences, therefore we reasoned that antigen/CD1 chimeras containing the different CD1 cytoplasmic tail sequences could optimally target antigens to the MHC class II antigen presentation pathway. Evaluation of trafficking patterns revealed that all four human CD1-derived targeting sequences delivered antigen to the MHC class II antigen presentation pathway, to early/recycling, early/sorting and late endosomes/lysosomes. There was a preferential requirement for different CD1 targeting sequences for the optimal presentation of an MHC class II epitope in the following hierarchy: CD1b > CD1d = CD1c > > > CD1a or untargeted antigen. Therefore, the substitution of the CD1 ectodomain with heterologous proteins results in their traffic to distinct intracellular locations that intersect with MHC class II and this differential distribution leads to specific functional outcomes with respect to MHC class II antigen presentation. These findings may have implications in designing DNA vaccines, providing a greater variety of tools to generate T-cell responses against microbial pathogens or tumours.

Indexed as

Antigen PresentationAntigens, BacterialAntigens, CD1CD4-Positive T-LymphocytesChaperonin 10Dose-Response Relationship, ImmunologicEndosomesEpitopes, T-LymphocyteGreen Fluorescent ProteinsHeLa CellsHistocompatibility Antigens Class IIHumansInterferon-gammaLymphocyte ActivationMycobacterium lepraeRecombinant Fusion ProteinsAntigens, BacterialAntigens, CD1Chaperonin 10Epitopes, T-LymphocyteGreen Fluorescent ProteinsHistocompatibility Antigens Class IIInterferon-gammaRecombinant Fusion ProteinsRecombinant Proteins

Identifiers

PMID17635609
PMCPMC2266034
OpenAlexW1988883856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.